TY - JOUR
T1 - Appropriate timing of surveillance intervals with whole-body 18F-FDG PET/CT following treatment for sinonasal malignancies
AU - Ozturk, Kerem
AU - Gencturk, Mehmet
AU - Caicedo-Granados, Emiro
AU - Li, Faqian
AU - Cayci, Zuzan
N1 - Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2019/9
Y1 - 2019/9
N2 - Purpose: To assess the ideal timing of posttreatment whole-body 18F-FDG PET/CT examination as routine surveillance to determine local recurrence (R), lymph node metastasis (LM), and distant metastasis (DM) of sinonasal malignancies and to investigate the effect of 18F-FDG PET/CT on survival. Methods: An overall 80 patients who had undergone a total of 197 posttreatment whole-body 18F-FDG PET/CT examinations for sinonasal malignancy were retrospectively examined after institutional review board approval. Patients were grouped regarding the time intervals (<1 month, 1–3 months, 3–6 months, 6–12 months, 12–18 months and >18 months) after the conclusion of treatment. Differences in diagnostic accuracy due to different follow-up intervals were calculated by receiver operator curves (ROC) and a Cox proportional hazards model was used to assess the prognostic value of surveillance 18F-FDG PET/CT. Results: Considering the time intervals of posttreatment 18F-FDG PET/CT scans, the negative predictive value and positive predictive value of the 18F-FDG PET/CT examinations to predict overall recurrence in 1–3 months (100 and 100%, respectively) and >18 months (100 and 95%, respectively) were higher than for recurrence detection in <1 month (50 and 100%, respectively), 3–6 months (81 and 93%, respectively), 6–12 months (79 and 87%, respectively), and 12–18 months (75 and 80%, respectively) (p < 0.05). Positive findings on 18F-FDG PET/CT scans were also independent predictors of poorer overall survival (OS) (p < 0.05). Conclusions: Whole-body 18F-FDG PET/CT is capable of identifying recurrences following treatment, using an optimal time interval for scanning of 1–3 months and >18 months after therapy.
AB - Purpose: To assess the ideal timing of posttreatment whole-body 18F-FDG PET/CT examination as routine surveillance to determine local recurrence (R), lymph node metastasis (LM), and distant metastasis (DM) of sinonasal malignancies and to investigate the effect of 18F-FDG PET/CT on survival. Methods: An overall 80 patients who had undergone a total of 197 posttreatment whole-body 18F-FDG PET/CT examinations for sinonasal malignancy were retrospectively examined after institutional review board approval. Patients were grouped regarding the time intervals (<1 month, 1–3 months, 3–6 months, 6–12 months, 12–18 months and >18 months) after the conclusion of treatment. Differences in diagnostic accuracy due to different follow-up intervals were calculated by receiver operator curves (ROC) and a Cox proportional hazards model was used to assess the prognostic value of surveillance 18F-FDG PET/CT. Results: Considering the time intervals of posttreatment 18F-FDG PET/CT scans, the negative predictive value and positive predictive value of the 18F-FDG PET/CT examinations to predict overall recurrence in 1–3 months (100 and 100%, respectively) and >18 months (100 and 95%, respectively) were higher than for recurrence detection in <1 month (50 and 100%, respectively), 3–6 months (81 and 93%, respectively), 6–12 months (79 and 87%, respectively), and 12–18 months (75 and 80%, respectively) (p < 0.05). Positive findings on 18F-FDG PET/CT scans were also independent predictors of poorer overall survival (OS) (p < 0.05). Conclusions: Whole-body 18F-FDG PET/CT is capable of identifying recurrences following treatment, using an optimal time interval for scanning of 1–3 months and >18 months after therapy.
KW - F-FDG PET/CT
KW - Follow-up
KW - Sinonasal malignancies
KW - Surveillance
KW - Timing
UR - http://www.scopus.com/inward/record.url?scp=85068498190&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068498190&partnerID=8YFLogxK
U2 - 10.1016/j.ejrad.2019.07.004
DO - 10.1016/j.ejrad.2019.07.004
M3 - Article
C2 - 31439262
AN - SCOPUS:85068498190
SN - 0720-048X
VL - 118
SP - 75
EP - 80
JO - European Journal of Radiology
JF - European Journal of Radiology
ER -